|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,151.60 INR | +1.25% |
|
+3.49% | -2.12% |
| 19/03 | Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India | RE |
| 18/03 | Mankind Pharma buys Rivotril brand from Roche for India | RE |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 2,507.74 | +18.01% | 19 | ||||||
| 1,209.86 | +30.51% | 29 | ||||||
| 251.08 | +7.22% | 24 | ||||||
| 249 | +19.49% | 29 | ||||||
| 352.62 | +10.19% | 13 | ||||||
| 220.36 | +7.52% | 21 | ||||||
| 129.81 | +9.02% | 27 | ||||||
| 154.13 | +1.1% | 21 | ||||||
| 352.28 | -0.85% | 29 | ||||||
| 307.67 | +18.15% | 22 | ||||||
| 158.36 | +15.05% | 28 | ||||||
| 28.97 | +5.1% | 27 | ||||||
| 63.04 | +4.77% | 25 | ||||||
| 96.18 | +17.27% | 23 | ||||||
| 20.48 | -4.45% | 20 | ||||||
| 548.45 | +24.31% | 29 | ||||||
| 9,923.33 | +18.86% | 15 | ||||||
| 6,036.87 | +8.07% | 15 | ||||||
| 80.33 | +42.6% | 17 | ||||||
| 47.58 | +15.76% | 19 | ||||||
| Average | 1,136.91 | +13.39% | 23 | ||||||
| Weighted average by Cap. | 673.16 | +14.02% | 24 |
- Stock Market
- Equities
- MANKIND Stock
- Sector Mankind Pharma Limited
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition